Abstract
Twenty-three patients with metastatic non-oat cell bronchogenic carcinoma (MNOBC) were treated with cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP) after radiation therapy. Objective responses were seen in 11 of 23 patients (48%) with a projected median survival time of 12.5 months for responding patients and patients with stable disease. Lung, liver, and cutaneous sites of involvement proved to be highly responsive; bone involvement was less responsive. CAMP is an effective combination in the treatment of MNOBC and its use in patients with less advanced disease should be explored.
MeSH terms
-
Adenocarcinoma / drug therapy
-
Adenocarcinoma, Bronchiolo-Alveolar / drug therapy
-
Adult
-
Aged
-
Bone Neoplasms / drug therapy
-
Brain Neoplasms / drug therapy
-
Brain Neoplasms / radiotherapy
-
Carcinoma, Bronchogenic / drug therapy*
-
Carcinoma, Squamous Cell / drug therapy
-
Cyclophosphamide / therapeutic use*
-
Doxorubicin / therapeutic use*
-
Drug Therapy, Combination
-
Female
-
Humans
-
Liver Neoplasms / drug therapy
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / radiotherapy
-
Male
-
Methotrexate / therapeutic use*
-
Middle Aged
-
Neoplasm Metastasis
-
Procarbazine / therapeutic use*
-
Skin Neoplasms / drug therapy
Substances
-
Procarbazine
-
Doxorubicin
-
Cyclophosphamide
-
Methotrexate